We measured the LPCAT level by an ELISA (enzyme-linked immunosorbent assay) for determining the LPCAT role in SCAP and evaluating the predictive values for LPCAT as disease severity and prognosis among CAP patients in the early stage. The gene discussed is MBOAT2; the disease is syringocystadenoma papilliferum.